Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Grifols Diagnostic Solutions Inc. is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners and 2 distinct art units. This suggests that the company's current patent applications cover different technical niches that fall under the jurisdiction of separate administrative groups at the patent office.
The busiest examiner, ZOU, NIANXIANG, is responsible for 1 pending office action. Because there are 2 pending office actions in total, each of the 2 distinct examiners is handling a single case. This lack of examiner concentration means that the company must navigate two independent prosecution paths. Practitioners should be prepared for different examination styles, as the 2 distinct art units may prioritize different aspects of the Biotechnology & Pharmaceuticals field during their reviews.
With 2 distinct examiners and 2 distinct art units involved, the portfolio is not centralized under a single authority. The busiest examiner, ZOU, NIANXIANG, handles 1 pending office action, which represents half of the active workload. This requires a flexible approach to prosecution that accounts for the specific requirements of each art unit and the individual tendencies of the examiners assigned to the Biotechnology & Pharmaceuticals filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZOU, NIANXIANG | 1 | 64.1% | +24.8% |
| SULLIVAN, DENNIS JOHN | 1 | 57.3% | +49.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18144930 | Methods and Compositions for Treating Aging-Associated Impairments with TIMP-2 Recombinant Proteins | SULLIVAN, DENNIS JOHN | 21d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18144930 | Methods and Compositions for Treating Aging-Associated Impairments with TIMP-2 Recombinant Proteins | SULLIVAN, DENNIS JOHN | 21d |
| 18555706 | COMPOSITIONS AND METHODS FOR STORING A BIOLOGICAL SAMPLE | ZOU, NIANXIANG | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18555706 | COMPOSITIONS AND METHODS FOR STORING A BIOLOGICAL SAMPLE | ZOU, NIANXIANG | 1671 | §103§112DP | Final Rejection | — | Pending | Oct 16, 2023 |
| 18144930 | Methods and Compositions for Treating Aging-Associated Impairments with TIMP-2 Recombinant Proteins | SULLIVAN, DENNIS JOHN | 1642 | §103§112 | Final Rejection | 21d | Pending | May 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial